| Accession |
PRJCA018901 |
| Title |
CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 |
| Relevance |
Medical |
| Data types |
Biomaker (PD-L1)
|
| Organisms |
Homo sapiens
|
| Description |
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer |
| Sample scope |
Multiisolate |
| Release date |
2023-08-08 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
2017L05147/2017L05148
|
|
|
|
| Submitter |
Dingwei
Ye (fuscc2012@163.com)
|
| Organization |
Fudan University Shanghai Cancer Center |
| Submission date |
2023-08-08 |
